<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v9i11.12981</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Research on the Mechanism of the lncRNA DLX6-AS1/miR-26a/PTEN Axis in Regulating the Activation of Hepatic Stellate Cells in Post-hepatitis Liver Fibrosis: An Analysis Based on Systematic Validation and Clinical Translation Methods</title><url>https://artdesignp.com/journal/JCNR/9/11/10.26689/jcnr.v9i11.12981</url><author>WangYan,GaoChao,FeiDongqin,ZhangFang,ZhangQi</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>11</issue><history><date date-type="pub"><published-time>2025-12-09</published-time></date></history><abstract>Objective: To elucidate the role and clinical potential of the lncRNA DLX6-AS1/miR-26a/PTEN axis in liver fibrosis. Methods: Systematic studies were conducted using cellular and animal models through causal validation, bivariate experiments, single-cell sequencing, ROC analysis of clinical samples, and humanized mouse models. Results: LncRNA DLX6-AS1 inhibited PTEN by adsorbing miR-26a, promoting hepatic stellate cell activation in a dose/time-dependent manner; the axis demonstrated excellent diagnostic performance (AUC &amp;gt; 0.9), and its inhibitors effectively reversed fibrosis in vivo. Conclusion: This study provides new biomarkers and targeted therapeutic strategies for liver fibrosis.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Ortiz C, Schierwagen R, Schaefer L, et al., 2021, Extracellular Matrix Remodeling in Chronic Liver Disease. Current Tissue Microenvironment Reports, 2(3): 41–52.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Bedossa P, Paradis V, 2003, Liver Extracellular Matrix in Health and Disease. Journal of Pathology, 200(4): 504–515.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Bataller R, Brenner D, 2005, Liver Fibrosis. Journal of Clinical Investigation, 115(2): 209–218.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Qian Y, Song W, Wu X, et al., 2021, DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290. Digestive Diseases and Sciences, 66(2): 460–473.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Qu G, Li X, Jin R, et al., 2024, MicroRNA-26a Alleviates Tubulointerstitial Fibrosis in Diabetic Kidney Disease by Targeting PAR4. Journal of Cellular and Molecular Medicine, 28(3): e18099.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Bian E, Huang C, Ma T, et al., 2012, DNMT1-Mediated PTEN Hypermethylation Confers Hepatic Stellate Cell Activation and Liver Fibrogenesis in Rats. Toxicology and Applied Pharmacology, 264(1): 13–22.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Yang Y, Chen Y, Feng D, et al., 2024, Ficus hirta Vahl. Ameliorates Liver Fibrosis by Triggering Hepatic Stellate Cell Ferroptosis Through the GSH/GPX4 Pathway. Journal of Ethnopharmacology, 334: 118557.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Wang P, Li J, Ji M, et al., 2024, The Vitamin D Receptor Mitigates Carbon Tetrachloride-Induced Liver Fibrosis by Downregulating YAP. J Hazard Mater, 478: 135480.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Yao Y, Zuo X, Shao F, et al., 2024, Jaceosidin Inhibits the Progression of Hepatic Fibrosis by Suppressing the VGLL3/HMGB1/TLR4 Signaling Pathway. Phytomedicine, 128: 155502.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Qin H, Yang Y, Jiang B, et al., 2021, Cancer-Associated Fibroblasts Upregulate SOX9 in Prostate Cancer to Promote Tumor Progression Through the HGF/c-Met-FRA1 Signaling Pathway. FEBS J, 288(18): 5406–5429.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><p>Liu X, Peng D, Cao Y, et al., 2021, The Upregulated lncRNA DLX6-AS1 Drives Hepatocellular Carcinoma Progression via the miR-513c/Cul4A/ANXA10 Axis. Cancer Gene Ther, 28(5): 486–501.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><p>Zhao R, Yuan H, Jiang Y, et al., 2025, Development and Validation of an Integrative Risk Identification Model Based on 54 Biomarkers for Multi-Cancer in 42,666 Individuals: A Population-Based Prospective Study to Guide Advanced Screening Strategies. Biomark Res, 13(1): 101.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><p>Hebert S, 1999, Molecular Mechanisms. Semin Nephrol, 19(6): 504–523.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
